InvestorsObserver is giving Avadel Pharmaceuticals PLC (AVDL) an Analyst Rating Rank of 80, meaning AVDL is ranked higher by analysts than 80% of stocks. The average projection by analysts for AVDL is $16.75 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Avadel Pharmaceuticals PLC Stock Today?
Avadel Pharmaceuticals PLC (AVDL) stock is higher by 5.08% while the S&P 500 is unmoved 0% as of 10:58 AM on Friday, Sep 25. AVDL has risen $0.26 from the previous closing price of $5.02 on volume of 237,752 shares. Over the past year the S&P 500 is higher by 9.03% while AVDL has risen 33.00%. AVDL earned $0.11 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 47.75.
Click Here to get the full report on Avadel Pharmaceuticals PLC (AVDL) Stock.